Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR
Table 1
Baseline characteristics of the study population.
Parameters
Placebo ()
Pioglitazone ()
value
Sex, M/F,
11/3
12/2
1.00
Age, yr
55.5 ± 10.9
56.2 ± 10.4
0.74
Body mass index, kg/m2
23.7 ± 4.9
24.5 ± 2.9
0.58
Systolic BP, mm Hg
124 ± 19
121 ± 16
0.72
Diastolic BP, mm Hg
78 ± 10
76 ± 10
0.55
Smoking
9
12
0.39
Fasting glucose, mmol/L
5.28 ± 0.57
5.32 ± 0.37
0.86
HbA1c, %
5.42 ± 0.59
5.18 ± 0.49
0.25
Total cholesterol, mmol/L
3.78 ± 0.76
3.61 ± 0.45
0.48
Triglycerides, mmol/L
1.75 ± 1.27
1.81 ± 1.23
0.89
HDL cholesterol, mmol/L
0.90 ± 0.17
0.88 ± 0.20
0.74
LDL cholesterol, mmol/L
2.35 ± 0.67
2.15 ± 0.49
0.34
Gensini score
12.6 ± 8.8
10.9 ± 5.1
0.54
hsCRP, mg/L
4.0 (0.8, 11.8)
2.9 (1.3, 12.3)
0.58
Treatment after stenting
Aspirin
14
14
1.00
Clopidogrel
14
14
1.00
Blocker
12
14
0.48
ACE inhibitors/ARBs
14
14
1.00
Statins
14
14
1.00
Data are reported as mean ± SD, median (interquartile range), or . BP, blood pressure; hs-CRP, high sensitivity C-reactive protein; ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker.
